



May 10, 2017

NxStage Medical Announces FDA Clearance for its New System One Hemodialysis System

LAWRENCE, Mass., May 10, 2017 /PRNewswire/ -- [NxStage Medical, Inc.](http://www.nxstage.com) (NASDAQ: NXTM), a leading medical technology company focused on advancing renal care, today announced that its next generation hemodialysis system has received FDA clearance. This innovative system consists of new features and capabilities, including a new touchscreen user interface and integrated blood pressure monitor designed to enhance ease of use for patients performing home hemodialysis.



"Early customer and patient feedback in the UK on our next generation system has been very positive, validating many of the benefits we expected," said Joseph E. Turk, president of NxStage Medical, Inc. "We are very excited to bring these new features and capabilities that are designed to significantly improve our patients' therapy experience to the US market. The touch screen interface provides an excellent platform to continue bringing new features and functionality moving forward."

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. The simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow™ SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on-site on-demand. Unlike conventional hemodialysis systems, the System One family of products requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health® platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. The System One is also used to provide a range of flexible therapy options in more traditional care settings such as hospitals and dialysis centers. Its safety and performance have been demonstrated by experience with more than 14 million treatments with over 30 thousand patients around the world. <http://www.nxstage.com/>.

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage has also established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's website at <http://www.nxstage.com> and www.nxstagekidneycare.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com



To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/nxstage-medical-announces-fda-clearance-for-its-new-system-one-hemodialysis-system-300455345.html>

SOURCE NxStage Medical, Inc.

News Provided by Acquire Media